Caribou Ends Clinical Pipeline After Financing Freeze, As Board Explores Strategic Alternatives

Caribou Biosciences is shutting down development of its clinical-stage pipeline and making a substantial workforce reduction after concluding that financing conditions for allogeneic CAR-T therapies no longer support continued investment. The company said it will halt all ongoing clinical trials and any further development of its donor-derived CAR-T candidates while its board reviews strategic alternatives.

Potential outcomes under that review include a merger, acquisition, business combination, or a transaction involving the company and/or its assets. In a LinkedIn post, CEO Rachel Haurwitz called the decision a “heartbreaking turn” and said the company still hopes other organizations with the necessary resources and commitment could advance the programs.

The announcement landed hard in the market. BioSpace reported that shares fell 43% to 64 cents apiece in early-market trading on Wednesday morning. The signal from the restructuring is that positive early clinical data are not enough on their own when a platform area loses access to financing.

The Data

Caribou’s active programs were vispa-cel, a CD19-targeting therapy for B cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA therapy for multiple myeloma. Both were in Phase 1 development.

For vispa-cel, Caribou had reported in June that the Phase 1 ANTLER trial produced an 82% overall response rate in patients with second-line large B cell lymphoma. The complete response rate was 67%, and median progression-free survival was 17.1 months. Safety was also a primary endpoint in ANTLER, and Caribou reported no cases of graft-versus-host disease or severe immune effector cell-associated neurotoxicity syndrome, with one instance of severe cytokine release syndrome. In March, the FDA had granted vispa-cel regenerative medicine advanced therapy designation.

For CB-011, Phase 1 data from the CaMMouflage study showed a 92% overall response rate in treated patients, with dose-limiting toxicities also serving as a primary endpoint. Caribou reported no cases of graft-versus-host disease, immune effector cell-associated enterocolitis, parkinsonism or severe ICANS.

Fierce Biotech added a competitive reference point, reporting that Caribou had said this summer that vispa-cel matched Bristol Myers Squibb’s Breyanzi and Kite Pharma’s Yescarta in median progression-free survival in its Phase 1 trial. Haurwitz wrote that vispa-cel was “the first allogeneic CAR-T cell therapy to demonstrate safety, efficacy and durability on par with autologous CAR-T cell therapies.” She also said the company had already agreed with the FDA on the design of a Phase 3 trial for vispa-cel.

The Commercial Picture

The company’s explanation for the reset was not a newly disclosed clinical problem but a funding problem. Haurwitz said the decision was “in no way a reflection of our belief” in vispa-cel and CB-011 and wrote that the barrier was the inability to secure enough capital “to responsibly advance” allogeneic CAR-T therapies.

That distinction matters because Caribou had previously presented itself as funded into the next stage of development. As of June 30, the company had $113.8 million in cash, cash equivalents and marketable securities. In its second-quarter report in August, Caribou said that amount was sufficient to fund dose-expansion assessments for CB-001 and start-up activities for the Phase 3 ANTLER-3 study for vispa-cel, and it estimated runway through the end of 2027.

The reversal suggests that runway math alone did not solve the next financing step. Caribou now expects to incur about $15 million to $19 million in restructuring costs.

Fierce Biotech framed the broader capital shift more explicitly. Investor and acquirer interest in cell therapy has lately favored in vivo approaches that use gene editing to direct a patient’s T cells without extracting cells from the body. The outlet cited activity from Eli Lilly, Johnson & Johnson, AstraZeneca and Moderna in that area and described the funding backdrop for allogeneic CAR-T developers as a “nuclear winter.” Against that backdrop, Caribou’s programs may have generated encouraging data but still failed to clear the newer threshold for financability.

The Road Here

Caribou was founded in 2011 by Jennifer Doudna, Rachel Haurwitz, Martin Jinek and James Berger. From the outset, the company focused on off-the-shelf CAR-T therapies for hematologic cancers and autoimmune diseases. The premise was that donor-derived cells could avoid long manufacturing times and reduce dependence on the condition of a patient’s own T cells.

As of Feb. 27, 2026, Caribou had 97 full-time employees. The company said the workforce reduction is expected to be mostly complete in the fourth quarter of 2026, but it did not disclose how many jobs will be affected.

The immediate implication is that Caribou is no longer trying to bridge to the next trial on its own balance sheet. It is trying to determine whether its assets have more value inside a better-capitalized organization than they do as a standalone allogeneic CAR-T company in the current market.